Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Wiestner

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
Blood|December 17, 2025
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 StudyAndy Itsara, Victoria M Rogness, Laura Samples, et al.
Blood|August 14, 2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBetty Y Chang, Michelle Francesco, Martin F M De Rooij, et al.
Plos One|February 11, 2020
Expression of the muscle-associated gene MYF6 in hairy cell leukemiaEvgeny Arons, Hong Zhou, Mark Sokolsky, et al.
Briefings in Bioinformatics|October 17, 2025
Numbat-multiome: inferring copy number variations by combining RNA and chromatin accessibility information from single-cell dataRuitong Li, Jean-Baptiste Alberge, Tina Keshavarzian, et al.
Blood|April 30, 2016
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphomaNakhle S Saba, Delong Liu, Sarah E M Herman, et al.
Haematologica|October 3, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibAndrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, et al.
Blood Advances|May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targetingMaissa Mhibik, Erika M Gaglione, David Eik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2016
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic LeukemiaAlba Matas-Céspedes, Anna Vidal-Crespo, Vanina Rodriguez, et al.
Haematologica|February 24, 2018
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trialRiccardo Bomben, Simone Ferrero, Tiziana D'Agaro, et al.
Blood|September 5, 2015
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibClare Sun, Xin Tian, Yuh Shan Lee, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Blood|December 17, 2025
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 StudyAndy Itsara, Victoria M Rogness, Laura Samples, et al.
Blood|August 14, 2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBetty Y Chang, Michelle Francesco, Martin F M De Rooij, et al.
Plos One|February 11, 2020
Expression of the muscle-associated gene MYF6 in hairy cell leukemiaEvgeny Arons, Hong Zhou, Mark Sokolsky, et al.
Briefings in Bioinformatics|October 17, 2025
Numbat-multiome: inferring copy number variations by combining RNA and chromatin accessibility information from single-cell dataRuitong Li, Jean-Baptiste Alberge, Tina Keshavarzian, et al.
Blood|April 30, 2016
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphomaNakhle S Saba, Delong Liu, Sarah E M Herman, et al.
Haematologica|October 3, 2015
Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibAndrew H Lipsky, Mohammed Z H Farooqui, Xin Tian, et al.
Blood Advances|May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targetingMaissa Mhibik, Erika M Gaglione, David Eik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2016
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic LeukemiaAlba Matas-Céspedes, Anna Vidal-Crespo, Vanina Rodriguez, et al.
Haematologica|February 24, 2018
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trialRiccardo Bomben, Simone Ferrero, Tiziana D'Agaro, et al.
Blood|September 5, 2015
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibClare Sun, Xin Tian, Yuh Shan Lee, et al.
Pageof 15